Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma

Abstract

Glioblastoma (GBM) remains the most malignant primary brain tumor, with a median survival rarely exceeding 2 years. Tumor heterogeneity and an immunosuppressive microenvironment are key factors contributing to the poor response rates of current therapeutic approaches. GBM‐associated macrophages (GAMs) often exhibit immunosuppressive features that promote tumor progression. However, their dynamic interactions with GBM tumor cells remain poorly understood. Here, we used patient‐derived GBM stem cell cultures and combined single‐cell RNA sequencing of GAM‐GBM co‐cultures and real‐time in vivo monitoring of GAM‐GBM interactions in orthotopic zebrafish xenograft models to provide insight into the cellular, molecular, and spatial heterogeneity. Our analyses revealed substantial heterogeneity across GBM patients in GBM‐induced GAM polarization and the ability to attract and activate GAMs—features that correlated with patient survival. Differential gene expression analysis, immunohistochemistry on original tumor samples, and knock‐out experiments in zebrafish subsequently identified LGALS1 as a primary regulator of immunosuppression. Overall, our work highlights that GAM‐GBM interactions can be studied in a clinically relevant way using co‐cultures and avatar models, while offering new opportunities to identify promising immune‐modulating targets.

Speeding up Glioblastoma Cancer Research: Highlighting the Zebrafish Xenograft Model

“…Among the laboratory-derived cell lines, the malignant GBM G1261, C6, U87, and U251 cell lines are usually used, with U87 and U251 predominating [140,152]. Primary patient-derived GBM cells have also been commonly used, as they display higher tumor-initiating potential [135,153]. Moreover, different methods have been used for GBM cell line transplantation, including organoids, neurospheres [154,155], and attached cultures, with the latter displaying the most successful potential [135].…”